Chamber and committees

In 2019-2020 the Scottish Government spent £15,849,263.61 in 2020 (1 April 2019 – 31 March 2020) and £11,106,352.64 in 2020/21 (1 April 2020 – 31 March 2021) on the maintenance of the Forth Road Bridge.

As promoter of the Grangemouth Flood Protection Scheme, Falkirk Council is required and committed to protecting natural habitats and enjoyment of the waterways while constructing flood defences that will safeguard communities.

The Scheme acknowledges the nationally and internationally-significant environmental designations present in the area which provide habitat for large numbers of birds. A precautionary approach has been adopted and consultation with the relevant Statutory Authorities is ongoing. An Appropriate Assessment and Habitats Regulations Appraisal (HRA) will form part of the Scheme documentation.

The Environmental Impact Assessment (EIA) considers the possible impact of the scheme and proposed mitigation measures under a number of headings; including wildlife and biodiversity, air quality, noise and vibration, landscape and cultural heritage. This assessment will be concluded later this year and be published when the Scheme is Notified.

Falkirk Council are responsible for the development of the Grangemouth Flood Protection Scheme. They have held a variety of public engagement events since 2019. Public information sessions will continue through 2022 and early 2023 using a variety of means including newsletters, social media updates, and drop in events.

A public exhibition will be held on the proposed flood defences before the Scheme goes into the formal Notification stage. The Notification process is a statutory requirement under Schedule 2 of the Flood Risk Management (Scotland) Act 2009.

A record of previous and future engagement activities are available from the scheme website ( www.grangemouthfloodscheme.com ).

Data on the proportion of NHS boards that have an effective patient care pathway for the early detection of liver disease is not available.

However, we understand there is variability in liver disease management across Scotland. The Scottish Government has identified the intelligent Liver Function Testing pathway (iLFT) used in Dundee, Tayside as best practice which is eligible for adoption across NHS Scotland as part of its Modern Outpatient Programme.

The Tayside iLFT group is collaborating with other NHS Scotland Boards to assist with the implementation of iLFT within their laboratories and primary care services.

In March 2021, we published our Respiratory Care Action Plan for Scotland, setting out our commitments to drive improvement in the prevention, diagnosis, care, treatment and support of people living with respiratory conditions such as bronchiectasis.

We recognise the importance of data in understanding respiratory care in Scotland. Our Plan contains a key commitment to build a core respiratory data set, which will enable the Scottish Government, NHS Boards and clinicians to identify improvements needed in delivery of respiratory care and also monitor how the implementation of our Plan is delivering better outcomes for people in Scotland.

At its first meeting in October, the Scottish Respiratory Advisory Committee (SRAC) identified data as one of the 3 key priorities for year 1 of implementation.

We have since established a sub-group consisting of clinical experts representing health boards across Scotland, Public Health Scotland and third sector representation to progress and deliver this commitment. The sub-group have held their first meeting and are in the process of commencing a scoping exercise on the data currently available across Scotland, before determining what data should be collected in the future in order to improve respiratory care.

Scottish Government is committed to ensuring that everyone with liver disease is able to access the best possible care and support and benefit from healthcare services that are safe, effective and person-centred.

We are working with the UK Government and other devolved administrations on the development of the revised UK-wide Clinical guidelines for alcohol treatment, which will include the treatment of liver diseases. The updated guidelines are expected to be published for consultation later this year.

We are improving our ability to detect cancer and to treat it successfully. That is why we continue to invest in our Detect Cancer Early Programme, which adopts a whole systems approach to diagnosing and treating cancer as early as possible. This will include the early detection of liver cancer.

General Practice and Primary Care multi-disciplinary teams will continue to play a key role in supporting patients with long-term condition management, including those with a diagnosis of liver disease, alongside specialist treatment services within Scotland’s healthcare system.

The intelligent Liver Function Testing pathway (iLFT) used in Dundee, Tayside has been identified as best practice of early detection of liver disease.

It uses an automated, algorithm-based system to further investigate abnormal liver function test results on initial blood samples from primary care.

The Scottish Government has identified the iLFT pathway as eligible for adoption across NHS Scotland as part of its Modern Outpatient Programme.

The Tayside iLFT group is collaborating with other NHS Scotland Boards to assist with the implementation of iLFT within their laboratories and primary care services.

I refer the member to the answer to question S6W-09214 on 28 June 2022. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers

The existing National Institute for Health and Care Excellence (NICE) guideline on the diagnosis and management of cirrhosis recommends that very heavy daily drinkers (men drinking up to 50 units per week or women 35 units per week) should be screened for cirrhosis using one of the newer non-invasive diagnostic technologies.

NICE suggests FibroScan and in 2020 published a Medtech innovation briefing around its use in primary care settings, but blood tests for fibrosis markers are also accurate and should be available to any clinician.

The Scottish Government currently has no plans to increase the use of FibroScan and enhanced liver fibrosis (ELF) tests in primary care in order to improve the early diagnosis of liver disease.

However, the Office for Health Improvement and Disparities is developing UK Clinical Alcohol Treatment Guidance, which is expected to include the issue of liver disease. These are expected to be published for consultation later this year. Once finalised, the Scottish Government will consider recommendations regarding early diagnosis of liver disease.

The Scottish Government has supported businesses with more than £4.7bn since the start of the pandemic. All funds have been allocated and no payments remain to be paid out by the Scottish Government. All Covid-19 business support funds have now closed.